VUMC-led trial demonstrates the inefficacy of two investigational drugs for treating severe COVID-19

Despite the success of vaccines for preventing COVID-19, and of drugs for treating the disease, outcomes for severely ill patients admitted to the hospital remains poor.

Related Keywords

United States ,American ,Seanp Collins ,Yves Rosenberg ,Matthews Shotwell ,Emily Henderson ,Division Of Cardiovascular Sciences ,Translational Research ,Journal Of The American Medical Association ,Vanderbilt Institute For Clinical ,Vanderbilt University Medical Center ,Us National Institutes Of Health Accelerating ,National Heart ,Blood Institute ,Department Of Emergency Medicine ,Clinical Research ,American Medical Association ,Wesley Self ,Emergency Medicine ,Senior Vice President ,Deputy Director ,Vanderbilt Institute ,Coronary Artery Disease ,Cardiovascular Sciences ,Health Accelerating ,Covid 19 ,Drugs ,Ce2 ,Ngiotensin ,Ngiotensin Converting Enzyme 2 ,Flood ,Blood Vessels ,Nzyme ,Heart ,Hospital ,Inflammation ,Migand ,Lungs ,Medicine ,Protein ,Eceptor ,Jenin ,Research ,Espiratory ,Cars ,Ars Cov 2 ,Evere Acute Respiratory ,Evere Acute Respiratory Syndrome ,Spike Protein ,Yndrome ,Virus ,